Key result
High urinary periostin excretion was independently associated with an increased risk of end-stage renal disease in patients with IgA nephropathy (HR 2.839; 95% CI 1.013-7.957; p=0.047).
Why the study?
Does urinary periostin excretion predict renal outcomes in patients with IgA nephropathy?
Cohort (n=314)
Does urinary periostin excretion predict renal outcomes in patients with IgA nephropathy?
Urinary periostin excretion at initial diagnosis correlates with renal fibrosis and independently predicts progression to end-stage renal disease in patients with IgA nephropathy.
May support periostin as IgA nephropathy biomarker; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: Periostin is a matricellular protein and plays a vital role in tissue regeneration, fibrosis and wound healing. However, data about its significance in nephrology are limited. We investigated the correlation between urinary periostin excretion and its clinical significance including renal histologic findings and prognosis in IgA nephropathy (IgAN). METHODS: Of 399 patients from a glomerulonephritis cohort recruited between January 2009 and December 2014, 314 were enrolled. Serum and urine periostin (uPOSTN) were measured using enzyme-linked immunosorbent assay. We divided the patients into 3 groups by uPOSTN/creatinine (uPOSTN/Cr): group 1 (undetectable), group 2 (lower than the median) and group 3 (higher than the median). RESULTS: The uPOSTN level was correlated with pathologic classifications and both initial and final IDMS-MDRD estimated glomerular filtration rates (eGFRs; p < 0.001). Histologically, group 3 patients were correlated with severe interstitial fibrosis/tubular atrophy (p = 0.004), interstitial inflammation (p = 0.007), hyaline arteriolosclerosis (p = 0.001) and glomerular sclerosis (p < 0.001). A higher initial uPOSTN/Cr level was associated with a greater decline in eGFR during follow-up (p = 0.043 when initial eGFR ≥60; p = 0.025 when eGFR <60 ml/min/1.73 m2), and the renal outcomes with end-stage renal disease (ESRD; p = 0.003), ESRD and/or eGFR decrease of >30% (p = 0.033) and ESRD and/or eGFR decrease of >50% (p = 0.046) occurred significantly more in group 3. In multivariate analysis, uPOSTN group 3 (hazards ratio 2.839, 95% CI 1.013-7.957; p = 0.047) was independently associated with ESRD in IgAN patients. CONCLUSION: uPOSTN/Cr value at initial diagnosis correlated with renal fibrosis and predicted the renal outcomes in patients with IgAN. It could be a promising urinary biomarker for renal fibrosis.
No takes yet. Share an insight, caveat, or question.
Hwang et al. (2016) conducted a cohort in IgA nephropathy (n=314). High urinary periostin excretion (uPOSTN/Cr higher than median) vs. Undetectable or lower than median uPOSTN/Cr was evaluated on End-stage renal disease (ESRD) (HR 2.839, 95% CI 1.013-7.957, p=0.047). High urinary periostin excretion was independently associated with an increased risk of end-stage renal disease in patients with IgA nephropathy (HR 2.839; 95% CI 1.013-7.957; p=0.047).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: